Search

everythinglearnresearchcommunity

for

Search:↓

Adolescents with severe alopecia incur significantly higher healthcare costs.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Many patients on new leukemia drugs had mild to moderate skin reactions.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Acute leukemias with the Philadelphia chromosome may be biphenotypic, and identifying this is important for proper treatment.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Nilotinib can cause generalized keratosis pilaris.

Alopecia areata can be transferred through stem cell transplants from affected siblings.

Imatinib can cause hair loss due to lichen planopilaris.

Chemotherapy and bone marrow transplant can cause permanent hair loss.

Nilotinib can cause keratosis pilaris, a skin condition.

A woman's hair turned white after taking a cancer drug called dasatinib.

A man got six skin cancers within a year after a cell transplant for leukemia but was cancer-free 32 months later; skin checks are important post-transplant.

Some minoxidil combinations can help differentiate leukemia cells without harming other cells.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.

Two teenage brothers had a rare, treatment-resistant form of female-pattern hair loss with unusual scalp changes.

Transplant success has improved with better immunosuppressive drugs and donor matching.

Blood stem cells are diverse, influenced by many factors, and understanding them is key for progress in regenerative medicine.

Mesenchymal Stem/Stromal Cells (MSCs) help in wound healing and tissue regeneration, but can also contribute to tumor growth. They show promise in treating chronic wounds and certain burns, but their full healing mechanisms and potential challenges need further exploration.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Recognizing and treating skin symptoms in essential thrombocythemia is crucial for patient quality of life.

Interferon and ribavirin can cause serious skin reactions and other health issues.

Actinic keratosis can lead to skin cancer, is more common in fair-skinned people, and can be reduced with sunscreen and treated effectively.

Stem cell therapy is promising for treating various health conditions, but more research is needed to understand its full potential and address challenges.

A man's gray hair got darker and thicker after using a psoriasis drug.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.